|
| related topics |
| {product, candidate, development} |
| {provision, law, control} |
| {personnel, key, retain} |
| {debt, indebtedness, cash} |
| {control, financial, internal} |
| {product, market, service} |
| {property, intellectual, protect} |
|
|
We have a history of operating losses and we may never achieve profitability. If we continue to incur losses or we fail to raise additional capital or receive substantial cash inflows from our partners by July of 2008, we may be forced to cease operations.
We may not be able to meet the covenants detailed in the Convertible Notes with MHR Institutional Partners IIA LP, which could result in an increase in the interest rate on the Convertible Notes and/or accelerated maturity of the Convertible Notes, which we would not be able to satisfy.
We are highly dependent upon collaborative partners to develop and commercialize compounds using our delivery agents.
Our collaborative partners control the clinical development of the drug candidates and may terminate their efforts at will.
Our collaborative partners are free to develop competing products.
Our product candidates are in various stages of development, and we cannot be certain that any will be suitable for commercial purposes.
Our future business success depends heavily upon regulatory approvals, which can be difficult and expensive to obtain.
Our business will suffer if we fail or are delayed in developing and commercializing an improved oral form of vitamin B12.
We may be at risk of having to obtain a license from third parties making proprietary improvements to our technology.
We face rapid technological change and intense competition.
We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.
Provisions of our corporate charter documents, Delaware law, and our stockholder rights plan may dissuade potential acquirors, prevent the replacement or removal of our current management and may thereby affect the price of our common stock.
Provisions of our corporate charter documents, Delaware law and financing agreements may prevent the replacement or removal of our current management and members of our Board of Directors and may thereby affect the price of our common stock.
Full 10-K form ▸
|
|
| related documents |
| 908259--3/16/2010--OXIGENE_INC |
| 1001233--3/16/2006--SANGAMO_BIOSCIENCES_INC |
| 908259--3/14/2006--OXIGENE_INC |
| 1013238--3/31/2006--ARADIGM_CORP |
| 1110803--3/6/2006--ILLUMINA_INC |
| 1120438--3/15/2006--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
| 318306--5/1/2006--ACCESS_PHARMACEUTICALS_INC |
| 352747--3/16/2007--UNIGENE_LABORATORIES_INC |
| 873303--3/10/2009--AVI_BIOPHARMA_INC |
| 72444--3/10/2010--NABI__BIOPHARMACEUTICALS |
| 873303--3/16/2010--AVI_BIOPHARMA_INC |
| 897075--3/14/2007--REPROS_THERAPEUTICS_INC. |
| 1023024--3/31/2006--BIOSANTE_PHARMACEUTICALS_INC |
| 1020214--2/27/2006--CERUS_CORP |
| 1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC |
| 908259--3/14/2008--OXIGENE_INC |
| 908259--3/14/2007--OXIGENE_INC |
| 1012270--3/16/2007--COLLAGENEX_PHARMACEUTICALS_INC |
| 1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC |
| 708717--10/14/2008--ALFACELL_CORP |
| 799698--4/3/2006--CYTRX_CORP |
| 887247--4/2/2007--CELLEGY_PHARMACEUTICALS_INC |
| 12239--4/4/2008--SPHERIX_INC |
| 817785--4/4/2007--IMMUNE_RESPONSE_CORP |
| 874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA |
| 886163--3/31/2006--LIGAND_PHARMACEUTICALS_INC |
| 907562--3/3/2006--DYAX_CORP |
| 1120438--3/16/2007--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
| 873303--3/16/2007--AVI_BIOPHARMA_INC |
| 873303--3/16/2006--AVI_BIOPHARMA_INC |
|